![Luiz Belardinelli](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Luiz Belardinelli
Hoofd Techniek/Wetenschap/O&O bij InCarda Therapeutics, Inc.
Profiel
Luiz Belardinelli is currently the Chief Medical Officer at InCarda Therapeutics, Inc. He previously worked as the Senior Vice President-Pharmacology at CV Therapeutics, Inc.
Actieve functies van Luiz Belardinelli
Bedrijven | Functie | Begin |
---|---|---|
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Hoofd Techniek/Wetenschap/O&O | 05-04-2016 |
Eerdere bekende functies van Luiz Belardinelli
Bedrijven | Functie | Einde |
---|---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Corporate Officer/Principal | 02-05-2011 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 2 |
---|---|
CV Therapeutics, Inc.
![]() CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
InCarda Therapeutics, Inc.
![]() InCarda Therapeutics, Inc. BiotechnologyHealth Technology InCarda Therapeutics, Inc. develops cardiovascular disease treatment through pulmonary delivery of established drugs. It also develops an inhaled therapy intended to treat paroxysmal atrial fibrillation. The company was founded by Narasimhan Rangachari, John S. Patton, Gregory M. Marcus and Carlos A. Schuler in 2009 and is headquartered in Newark, CA. | Health Technology |